Columnist Oluwatosin Adesoye highlights a discrepancy between medical literature and patient experiences regarding ...

The U.S. Food and Drug Administration (FDA) has granted priority review — a decision that could speed a drug’s approval — to an application for the oral therapy mitapivat for sickle cell disease (SCD) ...

Sickle cell disease (SCD) prognosis varies depending on disease severity and other factors, but the overall life expectancy for the inherited blood disorder has increased notably over recent decades.

Mutations in the HBB gene cause SCD by leading to the production of a faulty version of hemoglobin (the protein that helps red blood cells transport oxygen), which tends to clump inside red blood ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google For individuals living with sickle cell disease (SCD), daily life ...

Sickle cell disease (SCD) may be cured in some individuals by a stem cell transplant. There also are several approved therapies to help manage the condition and its related complications. Some of the ...

Casgevy (exagamglogene autotemcel) is now approved in the U.S. to treat children as young as 2 with sickle cell disease (SCD) and recurrent vaso-occlusive crises (VOCs). The U.S. Food and Drug ...

Beam Therapeutics plans to ask the U.S. Food and Drug Administration (FDA) to approve ristoglogene autogetemcel, or risto-cel, its single-dose, gene-edited cell therapy candidate for people with ...

A camp in North Carolina offers children living with sickle cell disease the chance to build confidence, independence, and emotional strength while connecting with others who also live with a chronic ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google Children with sickle cell anemia, the most common and severe form ...

A low dose of Vascarta‘s VAS-101, a curcumin-based gel being developed for sickle cell disease (SCD), was well tolerated and showed early signs of reducing red blood cell sickling, pain, and fatigue ...

A European Medicines Agency committee has issued a positive opinion on the gene-editing therapy Casgevy (exagamglogene autotemcel) in treating sickle cell disease (SCD) and transfusion-dependent beta ...